Suppr超能文献

印度的糖尿病管理:护理模式——印度医生综合临床实践调查的结果与分析

Managing diabetes in India: paradigms in care--outcomes and analysis in a comprehensive, clinical practice survey of Indian physicians.

作者信息

Sadikot Shaukat M, Singh Ved

机构信息

Jaslok Hospital and Research Centre, Mumbai 400026.

出版信息

J Indian Med Assoc. 2011 Nov;109(11):839-42, 844-8.

Abstract

Diabetes continues to be a pandemic despite huge strides in the awareness and management of the condition. The incidence of diabetes has been projected to rise by almost 170% in most of the developing countries including India. Currently, about 50 million people suffer from diabetes in India with the figures expected to reach 87 million by the year 2030. To assess the management trends in India, a cross-section of doctors across all the major zones of the country were requested to answer a set of questions based on a case profile. Approximately 1000 doctors from all corners of India provided their feedback on various issues of diabetes management. The patient profile was that of an overweight 46-year-old Indian female with hypertension, diabetes and dyslipidaemia with a history of recurrent urinary tract infection (UTI). Almost 84.5% of doctors concurred with the diagnosis of metabolic syndrome for this patient. The awareness about diabetes being a comorbidity as well as a cause for recurrent UTI was high with 86% of doctors choosing diabetes as a cause for recurrent UTI. Around 94% of doctors chose metformin as the drug of choice for the management of this patient. A total of 74% of doctors chose the combination of metformin and sulfonylurea for the management of postprandial hyperglycaemia. Opinions were divided on the choice of drugs for the management of diabetes in a non-obese patient with 31% of doctors still choosing metformin as the drug of choice as per the American Diabetes Association 2009 guidelines and 66% of doctors choosing glimeperide as the first choice in a non-obese patient in concordance with the Association of Physicians of India/Indian College of Physicians (API/ICP) guidelines on diabetes. However, 95% of doctors unanimously chose metformin as the drug of choice in patients with abdominal obesity and diabetes. Almost 83% of doctors were aware that Indians have a genetic predisposition to diabetes due to an inherently smaller beta cell mass associated with insulin resistance. Majority of the physicians were also aware of the adverse effects of most of the antidiabetic drugs with 86% of the physicians identifying hydrochlorothiazide as the cause of worsening uric acid levels in diabetics, when used for the management of hypertension. Practice patterns in India generally conform to guidelines. The survey also demonstrated that majority of the physicians are aware of the different complexities associated with the management of diabetes.

摘要

尽管在糖尿病的认知和管理方面取得了巨大进展,但糖尿病仍是一种大流行病。预计在包括印度在内的大多数发展中国家,糖尿病发病率将上升近170%。目前,印度约有5000万人患有糖尿病,预计到2030年这一数字将达到8700万。为了评估印度的管理趋势,要求该国所有主要地区的一组医生根据病例概况回答一系列问题。来自印度各地的约1000名医生就糖尿病管理的各种问题提供了反馈。患者概况为一名46岁超重的印度女性,患有高血压、糖尿病和血脂异常,有复发性尿路感染(UTI)病史。近84.5%的医生同意该患者患有代谢综合征的诊断。86%的医生认为糖尿病是复发性UTI的一个合并症及病因,对糖尿病作为合并症以及复发性UTI病因的认知度很高。约94%的医生选择二甲双胍作为该患者的治疗药物。共有74%的医生选择二甲双胍和磺脲类药物联合治疗餐后高血糖。对于非肥胖糖尿病患者的药物选择存在分歧,31%的医生仍根据2009年美国糖尿病协会指南选择二甲双胍作为首选药物,66%的医生根据印度医师协会/印度医师学院(API/ICP)糖尿病指南选择格列美脲作为非肥胖患者的首选药物。然而,95%的医生一致选择二甲双胍作为腹部肥胖合并糖尿病患者的首选药物。近83%的医生意识到,由于印度人天生的β细胞量较小且伴有胰岛素抵抗,他们在遗传上易患糖尿病。大多数医生也了解大多数抗糖尿病药物的不良反应,86%的医生认为在糖尿病患者使用氢氯噻嗪治疗高血压时,它会导致尿酸水平恶化。印度的治疗模式总体上符合指南。该调查还表明,大多数医生了解糖尿病管理中存在的不同复杂性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验